Go to the list of all blogs
Harry Richardson's Avatar
published in Blogs
Nov 19, 2026
TickeronGET DAILY SIGNALS
Eli Lilly (LLY) and McKesson (MCK): Balancing High-Growth Momentum With Steady Distribution Stability

Eli Lilly (LLY) and McKesson (MCK): Balancing High-Growth Momentum With Steady Distribution Stability

Key Takeaways

  • LLY is a high-growth pharmaceutical leader riding exceptional momentum in its cardiometabolic franchise, while MCK is a diversified pharmaceutical distributor delivering steadier, lower-volatility performance.
  • LLY has delivered materially stronger recent revenue growth and share-price momentum, while MCK offers a more defensive profile with a far lower beta.
  • Tickeron AI Verdict: LLY is the ticker of choice in this comparison, favored for its trend consistency, growth catalysts, and relative momentum.
  • Both names sit near record highs, making valuation and risk assessment a central consideration for investors evaluating each stock's market positioning.
  • For deeper context, explore LLY Major News and LLY Today's Price Move, as well as MCK Major News and MCK Today's Price Move, to follow the latest developments and intraday activity for each ticker.
  • To see how automated strategies are positioning across the market, explore Trending AI Robots.

Why These Two Healthcare Stocks Matter

Eli Lilly and Company (LLY) and McKesson Corporation (MCK) operate at different points in the pharmaceutical value chain. Lilly develops and manufactures drugs, with much of its recent expansion tied to treatments for diabetes and obesity. McKesson focuses on distribution and related healthcare services across North America. The contrast illustrates the trade-off between rapid growth at a premium valuation and a more stable, lower-multiple model. This setup is worth examining for investors interested in momentum within healthcare as well as those seeking greater resilience.

Eli Lilly's Position and Recent Results

Eli Lilly and Company (LLY) centers its efforts on neuroscience, cardiometabolic health, oncology, and immunology. The stock has held near record levels lately, driven by strong demand for Mounjaro and Zepbound. These two medicines account for most of the recent revenue increase. The company posted a notable year-over-year revenue jump and raised its full-year guidance, citing higher prescription volumes and broader insurance coverage, including through Medicare programs. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry. New developments include the launch of Foundayo, an oral obesity treatment, along with a pipeline of additional weight-loss candidates. Analyst views remain largely positive, though valuation levels and potential competition in the category warrant attention.

McKesson's Business and Recent Performance

McKesson Corporation (MCK) ranks among the largest pharmaceutical distributors in North America, supplying branded, generic, and specialty products to pharmacies, hospitals, and other providers. Its operations span distribution, oncology care, prescription technology, and medical-surgical supplies. The stock has traded near all-time highs following a quarter in which both adjusted earnings and revenue topped expectations, supported by prescription volume growth and strength in oncology and GLP-1 distribution. Recent moves include closing the acquisition of Precision Medicine Group, increasing its stake in Option Care Health, and extending a key customer agreement. From what I see, McKesson emphasizes consistent execution over rapid expansion, resulting in lower volatility and more modest valuation multiples compared with Lilly.

Contrasting Business Models and Metrics

The main distinction lies in their approaches. LLY relies on innovation and a concentrated set of high-value products, while MCK operates a high-volume, lower-margin distribution model with broader exposure across healthcare. On momentum, Lilly has shown stronger outperformance, whereas McKesson has advanced with a beta around 0.27, reflecting limited sensitivity to broader market moves. Risks differ as well: Lilly contends with product concentration and potential pricing pressure, while McKesson faces regulatory considerations and slower top-line growth. Valuation reflects these profiles, with Lilly commanding higher multiples and McKesson appearing more modest. I reviewed related patterns using Tickeron’s AI Pattern Search Engine to confirm the relative positioning.

Tickeron AI Assessment

Considering factors such as trend consistency, growth drivers, and relative momentum, Tickeron’s AI currently points to LLY as the stronger choice in this pairing. Its sustained trend, revenue acceleration, and near-term catalysts support a more favorable momentum profile than MCK. McKesson’s stability remains a clear advantage, yet its measured growth pace limits relative upside under present conditions. This view is probabilistic and tied to the current environment.

Using Tickeron’s AI Trading Bots for Strategy Insights

In my own analysis of names like these, I often consult Tickeron’s AI Trading Bots to test how various automated approaches might handle similar market conditions. The platform provides a range of bots with different styles, timeframes, and performance histories, allowing users to observe data-driven positioning across thousands of tickers. It serves as a practical way to explore strategy ideas without replacing individual research.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: LLY, MCK

Contributor

Harry Richardson — Algorithmic Trader & Strategy Developer Harry is an algorithmic trader specializing in impulse and breakout trading strategies across cryptocurrency and equity markets. With more than 10 years of experience in developing automated trading systems, he focuses on building structured algorithms designed to capture momentum while maintaining strict risk control. His approach combines quantitative analysis, real-market execution, and continuous performance monitoring. Vitalii prioritizes risk management, drawdown control, and strategy stability over short-term optimization, ensuring algorithms are adaptable to changing market conditions. He has developed and tested hundreds of automated strategies, working extensively with live trading environments, forward testing, and portfolio-level algorithm management. His work centers on transforming trading ideas into fully operational, scalable automated systems.


LLY sees MACD Histogram just turned negative

LLY saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 17, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 45 instances where the indicator turned negative. In 32 of the 45 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 71%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for LLY moved out of overbought territory on November 16, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 34 similar instances where the indicator moved out of overbought territory. In 22 of the 34 cases, the stock moved lower in the following days. This puts the odds of a move lower at 65%.

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 40 of 64 cases where LLY's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 62%.

The Momentum Indicator moved below the 0 level on November 18, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on LLY as a result. In 55 of 83 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 66%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where LLY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 54%.

LLY broke above its upper Bollinger Band on October 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

LLY moved above its 50-day moving average on October 14, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for LLY crossed bullishly above the 50-day moving average on October 15, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 7 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 54%.

Following a +1.80% 3-day Advance, the price is estimated to grow further. Considering data from situations where LLY advanced for three days, in 261 of 371 cases, the price rose further within the following month. The odds of a continued upward trend are 70%.

The Aroon Indicator entered an Uptrend today. In 219 of 300 cases where LLY Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 73%.

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is 4 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 59, placing this stock better than average.

The Tickeron Price Growth Rating for this company is 7 (best 1 - 100 worst), indicating outstanding price growth. LLY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 14 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 59 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 86 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: LLY's P/B Ratio (35.624) is slightly higher than the industry average of (-1.421). P/E Ratio (45.360) is within average values for comparable stocks, (21.700). Projected Growth (PEG Ratio) (1.170) is also within normal values, averaging (5.738). Dividend Yield (0.005) settles around the average of (0.038) among similar stocks. LLY's P/S Ratio (12.804) is very high in comparison to the industry average of (4.033).

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), ABBVIE (NYSE:ABBV), Merck & Co (NYSE:MRK), AstraZeneca PLC (NYSE:AZN), Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Pfizer (NYSE:PFE), Bristol-Myers Squibb Co (NYSE:BMY), Biogen (NASDAQ:BIIB).

Industry description

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

Market Cap

The average market capitalization across the Pharmaceuticals: Major Industry is 215.99B. The market cap for tickers in the group ranges from 4.8K to 1.21T. LLY holds the highest valuation in this group at 1.21T. The lowest valued company is NEWG at 4.8K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Major Industry was -9%. For the same Industry, the average monthly price growth was -8%, and the average quarterly price growth was -4%. OGN experienced the highest price growth at 0%, while SCLX experienced the biggest fall at -61%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Major Industry was 39%. For the same stocks of the Industry, the average monthly volume growth was 23% and the average quarterly volume growth was 19%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 59
P/E Growth Rating: 33
Price Growth Rating: 44
SMR Rating: 59
Profit Risk Rating: 59
Seasonality Score: 22 (-100 ... +100)
AI Screener 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a manufacturer of pharmaceutical products

Industry PharmaceuticalsMajor

Industry
Pharmaceuticals Major
Address
Lilly Corporate Center
Phone
+1 317 276-2000
Employees
50000
Web
https://www.lilly.com
Interact to see
Advertisement
UNH dropped -7.80% to $359.29 from Tuesday's $389.68 close, extending a two-session decline to roughly -13% and touching its lowest level in about seven weeks; the move occurred during regular market hours. The selloff accelerated on the CMS "CRUSH" proposal unveiled Nov. 16, which would extrapolate Medicare Advantage risk-adjustment audit findings from samples across entire contracts back to payment year 2018 and drop the fee-for-service adjuster; CMS estimates roughly $9 billion in industry clawbacks per payment year, and UnitedHealth, the largest MA insurer, has not sized its exposure.
AMD jumped +2.42%, rising $12.81 to $542.95 from Wednesday's close of $530.14, in early regular-session trading Thursday after extending gains built during premarket. The catalyst was Anthropic's IPO, priced at $83 a share above its marketed range and raising $81.3 billion in the largest listing on record; the debut revived sentiment across AI hardware names, and AMD is both an Anthropic supplier and a $2.5 billion investor in the lab.
Cerebras Systems (CBRS) dropped -6.48% to $97.43 in regular trading from the prior close of $104.18, reversing an early premarket gain of roughly +3%. No verified news or fundamental catalyst found for the intraday reversal; the move is likely profit-taking after the stock's +21% post-earnings rebound, consistent with a name that averages a ±4.5% daily swing and remains 65% below its first-day close.
CBRS fell -6.07% to $97.86 in the opening minutes of Wednesday's regular session, down from Tuesday's close of $104.18 — the move occurred during market hours, not premarket or after-hours. No verified news or fundamental catalyst found: no new filing, contract, or analyst action explains the drop, which is likely continued give-back from the post-earnings pop and the stock's habitual volatility — CBRS has averaged a ±4.5% daily swing over the past 60 sessions, and 17 of those sessions moved as much or more.
NVIDIA reported revenue of $115.84 billion for the third quarter of fiscal 2027, up 103% year over year and ahead of both company guidance and consensus estimates. Non-GAAP earnings per share (EPS, a measure of profit per outstanding share) came in at $2.68 , beating the roughly $2.47 analysts had expected.